United States
Print page content Print
Increase text size Decrease text size
Text Size

VIBRIN®

Campylobacter Fetus Bacterin

VIBRIN

Vibrin® is for vaccination of healthy cows and heifers as an aid in preventing campylobacteriosis (vibriosis) caused by Campylobacter fetus. Vibrin is prepared from an inactivated, concentrated suspension of Campylobacter fetus, bovine isolate, in a patented repository base.

Expand All
  • Uses

    Aids in the prevention of campylobacteriosis (vibriosis) caused by Campylobacter fetus.

    Key Features

    • Helps protect against campylobacteriosis (vibriosis), a common but difficult-to-detect reproductive disease of cattle.
    • A single dose is effective.
    • May be given as early as seven months before breeding, making it ideal for use at fall pregnancy check.
    • Single subcutaneous (SC) dose is 2mL, given to all breeding cows and heifers between 30 days and seven months before breeding.

    Safety and Efficacy

    Chemical inactivation renders Vibrin incapable of causing or spreading infectious disease. The special adjuvant base enhances and prolongs antigenic stimulation and may produce a localized vaccine granuloma. These are noninflammatory, however, and usually disappear in several weeks. Field use and extensive, controlled tests in breeding cattle under experimental conditions demonstrated that the serotype of Campylobacter fetus used in Vibrin was effective in prevention of campylobacteriosis.
    Pregnancy rates in vaccinated heifers were up to 44% higher than in nonvaccinated control heifers. All research conducted on Vibrin indicated a single dose is effective and there is no advantage in using multiple injections.

  • Precautions:

    1. Store at 2°–7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
    2. Use entire contents when first opened.
    3. Sterilized syringes and needles should be used to administer this vaccine.
    4. To avoid vaccination site trim-out, do not vaccinate within 60 days before slaughter.
    5. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
    6. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or is not administered in accordance with label directions.